<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the role of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (AZA) in Indian patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> over longer duration of time </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: One hundred fifty six patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> who were treated with AZA from January 1995 to December 2003 were reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>The indications for its use were as follows: (1) steroid dependent and steroid refractory disease; (2) <z:chebi fb="2" ids="2948">Azathioprine</z:chebi> monotherapy for naive patients with severe disease; and (3) combination therapy (AZA + <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> or <z:chebi fb="0" ids="20551">5-aminosalicylates</z:chebi>) for naive patients with severe disease </plain></SENT>
<SENT sid="3" pm="."><plain>The data included patient and disease demographics, efficacy and toxicity profile of AZA </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with a minimum duration of 6 mo use of AZA were included in this report </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of a total of 156 patients treated with AZA, 45 were excluded from analysis for the following reasons- (follow up less than 6 mo, n = 9; poor follow up, n = 18; adverse affects, n = 18) </plain></SENT>
<SENT sid="6" pm="."><plain>In steroid refractory/dependent group the mean number of relapses prior to and post initiation of AZA therapy were 3.28 (+/- 0.81) and 0.94 (+/- 0.29) respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Discontinuation of steroids could be accomplished in 12 of the 15 steroid dependent patients </plain></SENT>
<SENT sid="8" pm="."><plain>The proportion of patients with sustained remission of 1, 2, 3, 4 and 5 years duration were calculated </plain></SENT>
<SENT sid="9" pm="."><plain>Eighteen patients experienced adverse effects necessitating withdrawal of AZA (<z:hpo ids='HP_0001733'>pancreatitis</z:hpo>, n = 7; <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, n = 3; gastrointestinal intolerance, n = 2; <z:hpo ids='HP_0001596'>alopecia</z:hpo>, n = 2; and hematological, n = 4) while 13 patients needed dose reduction or temporary withdrawal of the drug </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: <z:chebi fb="2" ids="2948">Azathioprine</z:chebi> is well tolerated and has therapeutic benefits lasting as long as 4 years </plain></SENT>
<SENT sid="11" pm="."><plain>Adverse effects such as <z:hpo ids='HP_0001733'>pancreatitis</z:hpo>, <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, cytopenias and gastrointestinal symptoms do occur but are controlled by <z:e sem="disease" ids="C0152128" disease_type="Disease or Syndrome" abbrv="">drug withdrawal</z:e> only </plain></SENT>
</text></document>